Peer-reviewed veterinary case report
How sorafenib drug behaves in dogs with cancer after oral dose
By Cawley, Jacob R et al.·Published in Frontiers in veterinary science·2022·Ethos Veterinary Health, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors.
- Species:
- dog
Plain-English summary
Six dogs with cancer were given a medication called sorafenib to see how well it was tolerated and how it worked in their bodies. The dogs received a dose of 3 mg/kg, and blood samples were taken to measure the medication levels over time. The results showed that the medication peaked in their blood after about 4 hours and then decreased significantly by 24 hours. Importantly, the dogs did not experience any side effects from the treatment, suggesting that sorafenib could be a safe option for managing cancer in dogs. Further studies are planned to see how effective it is against tumors.
People also search for: dog cancer treatment sorafenib · side effects of sorafenib in dogs · how does sorafenib work for dog tumors
Abstract
Sorafenib is a multi-kinase small molecule inhibitor that targets serine/threonine and tyrosine kinases including the RAF kinase family, VEGFR-2, and PDGFR. The aim of this study was to evaluate the systemic pharmacokinetics of a previously defined tolerable oral dose of sorafenib in tumor-bearing dogs. Six client-owned dogs with a cytologic or histologic diagnosis of cancer were enrolled in this open-label, tolerability study. Dogs were administered sorafenib at an intended dose of 3 mg/kg and serum samples were obtained for analysis of sorafenib serum concentrations at 0, 1, 2, 6, 12, 24, 48, 72, 96, and 168 h post-drug administration. Median time to peak serum sorafenib concentration occurred at 4 h (range 2-12 h) resulting in an average serum concentration of 54.9 ± 33.5 ng/mL (118.2 ± 72.1 nM). Mean sorafenib levels declined by over 70% relative to peak serum concentrations by 24 h in all dogs, suggesting the value of at least twice daily administration. Doses of 3 mg/kg were well-tolerated and no patients in the study experienced adverse events that were attributable to sorafenib. Future trials in dogs with cancer are recommended at this dosing schedule to assess the effect of sorafenib administration on anti-tumor efficacy signals and relevant pharmacodynamic target modulation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35664857/